Clinical trials: Tauopathies
Alzheimer's Disease, Seizures
Seizure Activity in Alzheimer's Disease
The main purpose of this research project is to study how seizure-like activity affects the blood flow in the brain of patients with Alzheimer's disease (AD).
- Trial name
- NCT01554683
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Beth Israel Deaconess Medical Center
Dementia, Alzheimer Type
Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)
A recent study (Saltmarche et al., 21017) examined the effects of photobiomodulation (PBM), a kind of light therapy that uses red or near-infrared light to heal and protect tissue that has either been injured, is degenerating, or…
- Trial name
- PBM Dementia (NCT03160027)
- Testing
- Vielight Neuro Gamma
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Alzheimer's Disease
Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease
The study is a randomized, parallel, 4-dose design in subjects with mild-to-moderate Alzheimer's Disease. Subjects will be randomized to one of 4 doses of T3D-959.
- Trial name
- NCT02560753
- Testing
- T3D-959
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- T3D Therapeutics, Inc.
Alzheimer's Disease
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
- Trial name
- NCT05602727
- Testing
- MK-1942
- Where
- 74 sites in United States, Argentina and 9 more
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Senile Dementia, Alzheimer Type
A Study of Mobile Medical Supportive Care Program for Family Caregivers With Dementia Combined With Diabetes
The purpose of this project is to evaluate the effectiveness of the clinical application of a mHealth supportive care program for family caregivers with dementia combined with diabetes based on the supportive care framework.
- Trial name
- NCT06785857
- Testing
- mHealth Supportive Care Program, Offline supportive care
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yuanjiao Yan
Alzheimer Disease, Mild to Moderate Alzheimer Disease
A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease
This study is evaluating the safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT03520998
- Testing
- GRF6019
- Where
- 10 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alkahest, Inc.
Alzheimer Disease
The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the modulating effect of galantamine on circadian rhythm in patients with moderate Alzheimer's disease.
- Trial name
- NCT01181921
- Testing
- Galantamine
- Where
- Spain
- Volunteers
- 1 people
- Sponsor
- Janssen-Cilag, S.A.
Alzheimer's Disease
Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of aging. Neuropsychiatric symptoms (NPS) in AD are a major cause of burden to patients, caregivers, and society and are near-universal at some point in the…
- Trial name
- THC-AD (NCT02792257)
- Testing
- Dronabinol (Marinol®)
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Johns Hopkins University
Alzheimer Dementia (AD)
Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer
Evaluation of the safety and tolerability of a 20 mg once daily dose of memantine compared with 10 mg given twice daily in patients with dementia of Alzheimer's type and MMSE range 5-18.
- Trial name
- NCT02553928
- Testing
- Memantine (once daily), Memantine (twice daily)
- Where
- 6 sites in China
- Volunteers
- 62 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability
Patients with Alzheimer's disease (AD) can have seizures in addition to losing their memory and other mental functions (referred to as cognitive functions).
- Trial name
- LEV-AD (NCT02002819)
- Testing
- levetiracetam
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Minnesota
Alzheimer Disease
Valproate in Dementia (VALID)
The purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in…
- Trial name
- NCT00071721
- Testing
- Valproate
- Where
- 46 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Brain Health, Gestational Hypertension
Brain Health in Midlife
The purpose of this study is to learn if hypertensive disorders during pregnancy affects brain health in midlife.
- Conditions
- Brain Health, Gestational Hypertension, Alzheimer Disease, Dementia
- Trial name
- ADORE BRAIN (NCT06640842)
- Testing
- A combination of various tests and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy on brain health in midlife.
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Dementia of the Alzheimer's Type
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent…
- Trial name
- NCT00322153
- Testing
- memantine ER
- Where
- 83 sites in United States, Argentina and 2 more
- Volunteers
- 677 people
- Sponsor
- Forest Laboratories
Alzheimer's Disease (Incl Subtypes), Dementia
Improvisational Movement for People With Memory Loss and Their Caregivers
Dementia is a progressive decline in cognition that impairs a person's ability to perform activities of daily living. Changes in mood, gait, and balance are prominent secondary symptoms of Alzheimer's dementia that can…
- Conditions
- Alzheimer's Disease (Incl Subtypes), Dementia, Mild Cognitive Impairment
- Trial name
- IMOVE (NCT03333837)
- Testing
- Dance Group, Non-Group Dance, Social Group
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Wake Forest University Health Sciences
Empaglifozin, Physiological Effects of Drugs
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
Background: The drug empagliflozin treats diabetes. It lowers blood sugar by increasing glucose the kidneys excrete. This increases levels of ketones formed in the blood.
- Conditions
- Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors
- Trial name
- NCT03852901
- Testing
- empagliflozin (Jardiance) 25 mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute on Aging (NIA)
Hemodialysis Patient, Fatigue
The Effects of an App-based Acupressure on Alleviating Fatigue, Pruritus, and Sleep Quality Among Hemodialysis Patients
Objectives: To evaluate the effectiveness of an app-based self-guided acupressure intervention in alleviating fatigue and pruritus, and in improving sleep quality among hemodialysis patients.
- Trial name
- NCT07259369
- Testing
- app-based acupressure
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Taipei Medical University
Alzheimer's Disease
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).
- Trial name
- ExpeditionPRO (NCT02760602)
- Testing
- Solanezumab
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are 2:107,510,000-107,540,000 polymorphism non-carriers with the primary objective…
- Trial name
- NCT05267535
- Testing
- Piromelatine 20 mg
- Where
- 37 sites in United States, Canada
- Volunteers
- 216 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Alzheimer Disease (AD)
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
- Trial name
- NCT03518073
- Testing
- Zagotenemab
- Where
- 60 sites in United States, Canada and 1 more
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Dementia
STAR Caregivers - Virtual Training and Follow-up
This study evaluates the effectiveness of a caregiver outreach, training, and support program for caregivers of people with dementia who are using antipsychotic medication to manage agitation/aggression.
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burnout
- Trial name
- STAR-C-VTF (NCT04271046)
- Testing
- STAR-C-VTF, Control
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Kaiser Permanente